hrp0097p1-386 | Thyroid | ESPE2023

Very early diagnosis of Monocarboxylate Transporter 8 (MCT8) Deficiency by measuring Free Triiodothyronine (fT3) in Infancy

Dubinski Ilja , Weigand Heike , Schmidt Heinrich

Background: Monocarboxylate-transporter 8 (MCT8) deficiency, also known as Allan-Herndon-Dudley syndrome (AHDS), is associated with severe motoric and intellectual developmental delay. The pathophysiology is characterized by central hypothyroidism (due to transporter defect) and peripheral hyperthyroidism with thyrotoxicosis. There is often an increase in the peripheral T3 values and a decrease in the T4 values. In addition, numerous comorbidities can be held ...

hrp0097p2-80 | Adrenals and HPA Axis | ESPE2023

Cortisol and 11-oxygenated androgens in hair samples from children and adolescents with congenital adrenal hyperplasia

Dubinski Ilja , Krumbholz Aniko , Schmidt Heinrich

Background: Children with classical congenital adrenal hyperplasia (CAH) require glucocorticoid replacement. In addition to auxological examinations, laboratory measurements of e.g. 17-hydroxyprogesterone and androstenedione in serum are also necessary to assess the required dosage of hydrocortisone. Another possibility for measuring precursor steroids is hair analysis, which has not yet been carried out in children with this issue. The role of so-called 11-ox...

hrp0095p2-228 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Infection with SARS-CoV-2 may alter the half-life of desmopressin (DDAVP) in children with central diabetes insipidus

Dubinski Ilja , Bechtold-Dalla Pozza Susanne , Schmidt Heinrich

Background: Central diabetes insipidus (CDI) is characterised by a central deficiency of arginine vasopressin (AVP) with polyuria and polydipsia. The etiology is heterogeneous. The treatment of choice is the oral or nasal application of DDAVP (synthetic analogue of AVP). CDI in the context of coronavirus disease 2019 (COVID19) has been reported in an individual case.Case report: We present a 9-year old male with CDI of u...

hrp0086p1-p633 | Growth P1 | ESPE2016

Evaluation of Prepubertal Patients with Suspected Neurosecretory Dysfunction of Growth Hormone Secretion: Diagnostic Steps and Treatment Response

Sydlik Carmen , Weiszenbacher Claudia , Pozza Susanne Bechtold-Dalla , Schmidt Heinrich

Background and aims: Existence and diagnostic procedures of neurosecretory dysfunction (NSD) are still a matter of debate. The aim of the study was to analyse prediagnostic data of short-statured children with pathologic and normal spontaneous GH-secretion and to evaluate the effect of GH-therapy in NSD-patients.Methods: Of 90 children aged 3–16 years, in whom 12-hour night profiles for GH-secretion were performed (unicentric), in 49 NSD was diagnos...

hrp0084p2-426 | GH & IGF | ESPE2015

The Acid-Labile Subunit Dose Matters? Response to Human GH Treatment in Patients with Acid-Labile Subunit Deficiency

Bechtold Susanne , Roeb Julia , Weissenbacher Claudia , Sydlik Carmen , Schmidt Heinrich

Background: In patients with acid-labile subunit (ALS) deficiency, the inability to build ternary complexes results in a marked reduction of circulating total IGF1. Height reduction by heterozygosity is about 1 SD in comparison to wild type. In homozygosity or compound heterozygosity a height loss of −2 to −2.5 SD occurs. This is suggestive of a gene-dose effect. How does treatment with human GH influence height development in relation...

hrp0089p1-p037 | Bone, Growth Plate & Mineral Metabolism P1 | ESPE2018

Hypercalcaemia after Treatment with Denosumab in Children: Bisphosphonates as an Option for Therapy and/or Prevention?

Sydlik Carmen , Weissenbacher Claudia , Roeb Julia , Roland Durr Hans , Bechtold-Dalla Pozza Susanne , Schmidt Heinrich

Background: Pharmacologic options for treatment of osteolytic diseases especially in children are limited. Although not licensed for use, denosumab, a fully humanized antibody to RANKL, is used in children and shows good effects. Among others, one indication are giant cell tumors of the bone. Yet, there are reports of severe hypercalcemia after stop of denosumab, an adverse effect which is rarely seen in adults.Case reports: Four patients, aged 6, 13 and...

hrp0086p1-p141 | Bone & Mineral Metabolism P1 | ESPE2016

Off-Label Use of the Aromatase Inhibitor Letrozole in Pubertal Boys to Improve Final Height: Laboratory, Auxological and Bone Age Data

Schmidt Heinrich , Weissenbacher Claudia , Bechtold-Dalla Pozza Susanne , Roeb Julia , Sydlik Carmen

Background and aims: The aromatase inhibitor letrozole is used to improve final height in boys with predicted short stature by delaying bone age (BA) maturation due to suppression of estradiol levels. There are few data regarding its effects, especially when used as single medication.Methods: Ten pubertal boys with predicted low final height treated with letrozole 2.5 mg/d p.o. (no other medication) for up to 24 months were analysed for auxological, labo...

hrp0084p2-227 | Bone | ESPE2015

Longitudinal Bone Development in Patients with Classical Congenital Adrenal Hyperplasia: Data Using Peripheral Quantitative Computed Tomography

Bechtold Susanne , Duman Leyla , Weissenbacher Claudia , Roeb Julia , Pozza Robert Dalla , Schmidt Heinrich

Background and aims: Glucocorticoid treatment may influence bone and muscle development in patients with congenital adrenal hyperplasia (CAH). This study evaluated bone mineral density (BMD), bone geometry and muscle mass longitudinally throughout childhood.Methods: 18 patients (ten males, eight females) with classical CAH were included. BMD, bone geometry and muscle mass were measured using peripheral quantitative computed tomography (pQCT) in prepubert...

hrp0084p2-453 | Growth | ESPE2015

Cross-Sectional and Longitudinal Follow-Up of Changes in Glucose Metabolism in Prepubertal GH-Treated SGA-Patients: Results of an Unicentric Study

Sydlik Carmen , Bechtold Susanne , Weissenbacher Claudia , Roeb Julia , Buckl Matthias , Putzker Stefanie , Schmidt Heinrich

Background: Several studies show impaired glucose tolerance at a certain number of years after start of growth hormone in SGA-children.Objective and hypotheses: To perform a longitudinal and cross-sectional evaluation of the oGTTs (glucose-insulin-pairs) in prepubertal GH-treated SGA-children and to evaluate if ISI and HOMA are effective surrogates for glucose tolerance and of prognostic value (0–1 year data).Method: In 81 pre...

hrp0084p3-660 | Bone | ESPE2015

4 Years Follow-Up for 25OHD and iPTH in Vitamin D Substituted Patients with Diabetes Mellitus 1: An Unicentric Prospective Study

Weissenbacher Claudia , Roeb Julia , Sydlik Carmen , Pozza Susanne Bechtold Dalla , Marx Michael , Schmidt Heinrich

Background: Vitamin D deficiency/insufficiency seems to occur frequently in children and teenagers but it is a matter of debate if limits (<20 ng/ml; <30 ng/ml) are correct. Besides its effect in bone metabolism Vit-D is also supposed to have a positive influence in diabetes mellitus 1 (DM1).Objective and hypotheses: To study 25OHD and iPTH values in a group of patients (pts) (n=57) with DM1 without Vit-D substitution (2011), with 1000 I...